Business context and reporting period
The supplied filing is DelMar Pharmaceuticals, Inc.’s unaudited Form 10-Q for the quarter and nine months ended March 31, 2016, not a Tuhura Biosciences, Inc. filing for 2015 Q3 as indicated in the request metadata. The company is a clinical-stage cancer drug developer focused on VAL-083, including U.S. development for glioblastoma (GBM) and commercial rights in China, where the drug is approved for certain cancers.
Financial performance and position
| Metric | Period/value |
|---|---|
| Revenue | No revenue reported; the company said it did not expect near-term revenue. |
| Research and development expense | $790,323 for the quarter; $2,183,355 for nine months. |
| General and administrative expense | $630,226 for the quarter; $1,994,923 for nine months. |
| Net loss | $1,140,401 for the quarter, versus $2,086,719 restated; $5,408,479 for nine months, versus $4,223,087 restated. |
| Loss per share | $0.03 for the quarter and $0.12 for nine months; comparatives were $0.05 and $0.11, respectively. |
| Operating cash flow | Cash used of $3,592,218 for nine months, versus $3,044,475. |
| Cash and cash equivalents | $937,355 at March 31, 2016, down from $1,754,433 at June 30, 2015. |
| Liquidity and liabilities | Working capital of $439,470; current assets $1,115,436 and current liabilities $675,966. Total liabilities, including warrant derivative and stock-option liabilities, were $1,842,914. |
| Debt | No debt balance is reported at March 31, 2016. |
Margins are not meaningful because the company reported no revenue. Accumulated deficit was $24,028,040. The nine-month cash decline was partly offset by $2,791,902 of financing cash flow, including public-offering proceeds and warrant exercises.
Material changes versus prior comparable periods
- Nine-month operating expenses rose: R&D increased 13% and G&A increased 25%. Management attributed the increases principally to clinical development, data management and trial setup, as well as professional fees, travel and facilities costs.
- Nine-month net loss increased by $1,185,392. A $943,050 loss from warrant derivative remeasurement and a $270,965 loss related to warrant-term changes contributed; these non-cash valuation items can make reported results volatile.
- Quarterly net loss was lower than the restated prior-year quarter, chiefly reflecting a $276,584 derivative fair-value gain in the current quarter versus a $781,152 loss in the prior-year quarter.
- Common shares issued increased to 44,309,098 from 39,455,931 at June 30, 2015. The company also had 18,388,945 warrants outstanding at March 31, 2016.
Outlook, commentary, risks and unusual items
- Funding: Management said the company required additional funding to continue operations and development. After quarter-end, it raised $6.1 million gross through Series B preferred shares and estimated that available funds would support operations beyond the next 12 months. That estimate is subject to cost, timing and financing uncertainties.
- Clinical plans: Management selected a 40 mg/m² dosing regimen for advancement in refractory GBM and planned FDA discussions on a registration-directed study. A Phase II/III start within 6–9 months was described as possible, subject to FDA guidance and funding. Planned studies in newly diagnosed GBM and first-recurrence GBM also depended on approvals, collaboration arrangements and financing.
- Clinical evidence: Management cited interim, uncontrolled Phase I/II results, including estimated median survival of 8–9 months after bevacizumab failure among patients receiving an assumed therapeutic dose. The filing cautions that the study was small and non-controlled and that follow-up was ongoing.
- Post-quarter financing terms: Series B shares were convertible into common shares at $0.80, carried a cumulative 9% dividend payable in common shares, and included a low-single-digit royalty arrangement on qualifying product sales. The financing may create dilution and future royalty obligations.
- Restatement: Prior financial statements were restated for incorrectly accounting for 2013 placement-agent warrants as equity rather than derivative liabilities. The company stated the errors were material; restated 2015 nine-month loss increased by $174,831.
- Controls: Management reported remediation of a prior material weakness in accounting for complex financial instruments and concluded disclosure controls were effective at March 31, 2016.
- Other risks: The company depends on future financing, clinical and regulatory progress, and a third-party Chinese manufacturer/partner. Management warned that insufficient funding could delay, reduce or end development programs. No legal proceedings were reported.
Important facts for investors to verify
- Confirm the filing identity and period: the source is DelMar Pharmaceuticals’ 10-Q for March 31, 2016, not the company and period specified in the request.
- Verify the Series B financing’s net proceeds, conversion and dividend terms, royalty obligations, and resulting fully diluted share count.
- Review cash runway assumptions against the reported $937,355 quarter-end cash, operating cash use, and planned clinical spending.
- Assess the underlying clinical data, patient numbers, follow-up and statistical limitations before relying on interim survival estimates or projected trial timing.
- Review the warrant restatement, derivative valuation assumptions and continuing potential for non-cash earnings volatility and shareholder dilution.